🎉 M&A multiples are live!
Check it out!

Denali Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Denali Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Denali Therapeutics Overview

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.


Founded

2013

HQ

United States of America
Employees

422

Financials

LTM Revenue $12.5M

LTM EBITDA -$491M

EV

$1.4B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Denali Therapeutics Financials

Denali Therapeutics has a last 12-month revenue (LTM) of $12.5M and a last 12-month EBITDA of -$491M.

In the most recent fiscal year, Denali Therapeutics achieved revenue of n/a and an EBITDA of -$493M.

Denali Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Denali Therapeutics valuation multiples based on analyst estimates

Denali Therapeutics P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $12.5M XXX n/a XXX XXX XXX
Gross Profit $12.4M XXX n/a XXX XXX XXX
Gross Margin 99% XXX n/a XXX XXX XXX
EBITDA -$491M XXX -$493M XXX XXX XXX
EBITDA Margin -3933% XXX n/a XXX XXX XXX
EBIT -$537M XXX -$502M XXX XXX XXX
EBIT Margin -4304% XXX n/a XXX XXX XXX
Net Profit -$474M XXX -$423M XXX XXX XXX
Net Margin -3799% XXX n/a XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Denali Therapeutics Stock Performance

As of July 15, 2025, Denali Therapeutics's stock price is $15.

Denali Therapeutics has current market cap of $2.1B, and EV of $1.4B.

See Denali Therapeutics trading valuation data

Denali Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.4B $2.1B XXX XXX XXX XXX $-2.82

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Denali Therapeutics Valuation Multiples

As of July 15, 2025, Denali Therapeutics has market cap of $2.1B and EV of $1.4B.

Denali Therapeutics's trades at 4.1x EV/Revenue multiple, and -2.8x EV/EBITDA.

Equity research analysts estimate Denali Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Denali Therapeutics has a P/E ratio of -4.5x.

See valuation multiples for Denali Therapeutics and 12K+ public comps

Denali Therapeutics Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $2.1B XXX $2.1B XXX XXX XXX
EV (current) $1.4B XXX $1.4B XXX XXX XXX
EV/Revenue 109.4x XXX 4.1x XXX XXX XXX
EV/EBITDA -2.8x XXX -2.8x XXX XXX XXX
EV/EBIT -2.5x XXX -2.7x XXX XXX XXX
EV/Gross Profit 110.0x XXX n/a XXX XXX XXX
P/E -4.5x XXX -5.0x XXX XXX XXX
EV/FCF -2.5x XXX -3.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Denali Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Denali Therapeutics Margins & Growth Rates

Denali Therapeutics's last 12 month revenue growth is 441%

Denali Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.

Denali Therapeutics's rule of 40 is 386% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Denali Therapeutics's rule of X is -2831% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Denali Therapeutics and other 12K+ public comps

Denali Therapeutics Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 441% XXX n/a XXX XXX XXX
EBITDA Margin -3933% XXX n/a XXX XXX XXX
EBITDA Growth 4% XXX n/a XXX XXX XXX
Rule of 40 386% XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX -2831% XXX XXX XXX
Revenue per Employee XXX XXX n/a XXX XXX XXX
Opex per Employee XXX XXX $1.2M XXX XXX XXX
S&M Expenses to Revenue XXX XXX n/a XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX n/a XXX XXX XXX
Opex to Revenue XXX XXX n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Denali Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Denali Therapeutics M&A and Investment Activity

Denali Therapeutics acquired  XXX companies to date.

Last acquisition by Denali Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Denali Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Denali Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Denali Therapeutics

When was Denali Therapeutics founded? Denali Therapeutics was founded in 2013.
Where is Denali Therapeutics headquartered? Denali Therapeutics is headquartered in United States of America.
How many employees does Denali Therapeutics have? As of today, Denali Therapeutics has 422 employees.
Who is the CEO of Denali Therapeutics? Denali Therapeutics's CEO is Dr. Ryan J. Watts, PhD.
Is Denali Therapeutics publicy listed? Yes, Denali Therapeutics is a public company listed on NAS.
What is the stock symbol of Denali Therapeutics? Denali Therapeutics trades under DNLI ticker.
When did Denali Therapeutics go public? Denali Therapeutics went public in 2017.
Who are competitors of Denali Therapeutics? Similar companies to Denali Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Denali Therapeutics? Denali Therapeutics's current market cap is $2.1B
What is the current revenue of Denali Therapeutics? Denali Therapeutics's last 12 months revenue is $12.5M.
What is the current revenue growth of Denali Therapeutics? Denali Therapeutics revenue growth (NTM/LTM) is 441%.
What is the current EV/Revenue multiple of Denali Therapeutics? Current revenue multiple of Denali Therapeutics is 109.4x.
Is Denali Therapeutics profitable? Yes, Denali Therapeutics is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Denali Therapeutics? Denali Therapeutics's last 12 months EBITDA is -$491M.
What is Denali Therapeutics's EBITDA margin? Denali Therapeutics's last 12 months EBITDA margin is -3933%.
What is the current EV/EBITDA multiple of Denali Therapeutics? Current EBITDA multiple of Denali Therapeutics is -2.8x.
What is the current FCF of Denali Therapeutics? Denali Therapeutics's last 12 months FCF is -$557M.
What is Denali Therapeutics's FCF margin? Denali Therapeutics's last 12 months FCF margin is -4462%.
What is the current EV/FCF multiple of Denali Therapeutics? Current FCF multiple of Denali Therapeutics is -2.5x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.